ATHIRA PHARMA, INC. (LONA)

(10% Negative) ATHIRA PHARMA, INC. (LONA) Announces Delay in Lasofoxifene Development Timeline Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

QXO, INC. (QXO)

Director Kissel Mary E. 🟡 adjusted position in 9.3K shares (2 derivative) of QXO, Inc. (QXO) Transaction Date: May 05, 2026 | Filing ID: 000009

AXOGEN, INC. (AXGN)

📋 KATHY WEILER (Director) plans to sell 16K shares of AXOGEN, INC. (at $44.09 each, total $721K) Filed: May 07, 2026 | ID: 004178